PDCD1 and bladder transitional cell carcinoma: Supporting this possibility, the estimated mutational/neoantigen load was not clearly associated with anti-tumor immunity in bladder urothelial carcinomas treated with the anti PD-L1 drug atezolizumab31 and with response to PD-1 blockade in melanoma14.